Table 1 Characteristics of the study group
|  | Active LN (n = 16) | Stable LN (n = 10) | AAV (n = 6) | IgAN (n = 9) | MCD/FSGS (MCD, n = 4; FSGS, n = 1) | HC (n = 8) |
|---|---|---|---|---|---|---|
Age (years) | 31 (23–45) | 53 (31.75–61.25) | 52 (45.5–59.5) | 45 (35.5–57) | 53 (40.5–62) | 49.5 (40.5–55.5) |
Female, n (%) | 15 (93.75) | 10 (100) | 4 (66.67) | 8 (88.89) | 3 (60) | 6 (75) |
WBC count,  × 103/mL | 4.43 (3.32–6.54) | 4.30 (3.67–4.89) | 9.98 (6.89–15.37) | 8.1 (7.36–8.35) | 8.02 (6.28–10.01) | 5.44 (4.56–7.77) |
CRP, mg/L | 0.15 (0.07–1.15) | 0.05 (0.03–0.16) | 2.21 (0.38–10.35) | 0.03 (0.01–0.15) | 0.04 (0.02–0.05) | 0.02 (0.01–0.05) |
Serum BUN, mg/dL | 14.5 (12–18.75) | 15.5 (12.25–22.25) | 31 (21.75–58.75) | 17 (14.5–27) | 14 (11.5–23.5) | 15 (11–16) |
UPCR, mg/mg | 2.93 (0.90–5.87) | 0.21 (0.09–0.36) | 2.16 (1.233–2.97) | 1.6 (0.90–4.62) | 9.55 (3.99–16.88) | 0.05 (0.04–0.11) |
Serum anti-dsDNA, IU/ml | 512 (267.9–849.8) | 6.7 (2–155.9) | N/A | N/A | N/A | N/A |
C3, mg/dL | 44.5 (39.5–59.75) | 69.5 (47.75–84.75) | 106.5 (93.75–112.3) | 99 (85–124) | N/A | N/A |
C4, mg/dL | 8 (5.5–16) | 10.5 (4.5–21) | 25 (12.5–30.25) | 28 (20.5–32.5) | N/A | N/A |